Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Zoetis
ZTS
Zoetis
Regulatory Scrutiny And Trade Barriers Will Limit Market Potential
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
10 Aug 25
Updated
10 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$153.00
2.4% overvalued
intrinsic discount
10 Aug
US$156.62
Loading
1Y
-13.4%
7D
1.6%
Author's Valuation
US$153.0
2.4% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$153.0
2.4% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
11b
2014
2017
2020
2023
2025
2026
2028
Revenue US$10.6b
Earnings US$2.9b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.34%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$2.94b
Earnings '28
x
26.24x
PE Ratio '28
=
US$77.11b
Market Cap '28
US$77.11b
Market Cap '28
/
414.85m
No. shares '28
=
US$185.87
Share Price '28
US$185.87
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$152.69
Fair Value '25